European Journal of Surgical Oncology (EJSO) 2009-01-01

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study

R. Greil, M. Moik, R. Reitsamer, S. Ressler, M. Stoll, K. Namberger, C. Menzel, B. Mlineritsch, R. Greil, M. Moik, R. Reitsamer, S. Ressler, M. Stoll, K. Namberger, C. Menzel, B. Mlineritsch

Index: Eur. J. Surg. Oncol. 35(10) , 1048-54, (2009)

Full Text: HTML

Abstract

Purpose To evaluate the triplet combination of bevacizumab, capecitabine and docetaxel (XTA) as neoadjuvant therapy for breast cancer.

Related Compounds

Related Articles:

Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.

2014-01-01

[Biol. Pharm. Bull. 37(9) , 1550-4, (2014)]

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

2008-05-01

[Eur. J. Cancer 44(7) , 912-20, (2008)]

Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.

2009-01-01

[Clin. Cancer Res. 15(1) , 238-46, (2009)]

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment

2010-01-01

[Eur. J. Cancer 46 , 3022-36, (2010)]

Novel therapeutic strategies in development for prostate cancer.

2008-01-01

[Expert Opin. Investig. Drugs 17(1) , 13-22, (2008)]

More Articles...